Curis, Elan establish JV to develop hedgehog agonists; ended
Executive Summary
Along with Elan, Curis (regenerative medicine) has formed a joint venture they are calling Curis Newco, which will research and develop molecules that stimulate the hedgehog (Hh) signaling pathway, shown in previous studies to play a role in the development of the central and peripheral nervous systems.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice